Loading clinical trials...

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

NCT03895372•Pfizer

View on ClinicalTrials.gov

Summary

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female between the ages of 18 and 75 years.
•Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months.
•Have a PASI score of 12 or greater AND a Physician Global Assessment score of 3 (moderate) or 4 (severe).
•Have plaque-type psoriasis covering at least 10 % of total body surface area (BSA).

Exclusion Criteria

•Have non-plaque forms of psoriasis.
•Drug-induced psoriasis.
•Current active infection.
•Infected with Mycobacterium tuberculosis (TB).
•Have any history of malignancies.
•Require treatment with prohibited concomitant medications(s).
•Positive for hepatitis B or C, or human immunodeficiency virus (HIV).

Locations (45)

Alliance Dermatology and Mohs Center

Phoenix, Arizona, United States

Center for Dermatology and Plastic Surgery/CCT

Scottsdale, Arizona, United States

Center for Dermatology and Plastic Surgery

Scottsdale, Arizona, United States

Anaheim Clinical Trials, LLC

Anaheim, California, United States

Kern Research. Inc.

Bakersfield, California, United States

California Dermatology & Clinical Research Institute

Encinitas, California, United States

Imaging Healthcare Specialists

San Diego, California, United States

Medderm Associates Dermatology

San Diego, California, United States

University Clinical Trials

San Diego, California, United States

Renstar Medical Research

Ocala, Florida, United States

Key Dates

Start Date

June 27, 2019

Primary Completion Date

May 21, 2020

Completion Date

November 26, 2020

Last Updated

August 27, 2021

Enrollment

179

ACTUAL participants

Conditions

Psoriasis

Interventions

PF-06826647 or Placebo

DRUG

PF-06826647

DRUG

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments